Track the companies that matter to you. It's FREE! Click one of these fan favorites to get started: Apple; Google; Ford.



GSK Sees Positive Results on Asthma, COPD Drug Expected to Succeed Advair

Don't let it get away!

Keep track of the stocks that matter to you.

Help yourself with the Fool's FREE and easy new watchlist service today.

GlaxoSmithKline's (NYSE: GSK  ) inhaled drug candidate Relovair is showing positive results in two crucial studies evaluating the compound as a treatment for chronic obstructive pulmonary disease, or COPD.

The results boost the compound's prospects as a successor to GSK's blockbuster asthma and COPD drug Advair, whose patents have expired. London-based GSK, which maintains its U.S. headquarters in Research Triangle Park, North Carolina, and drug partner Theravance (Nasdaq: THRX  ) on Thursday released the results of two efficacy and safety phase 3 studies of Relovair that evaluated the compound in patients with COPD. GSK said both studies, which evaluated the compound in 6,000 patients, showed that Relovair demonstrated statistically significant improvement in patients compared to a placebo.

The two six-month studies will be combined with a separate 12-month study and included in the company's regulatory submissions. The company said that full results of all studies will be presented at future scientific meetings.

Relovair, which has been developed as a once-per-day inhaled drug, is also being studied as an asthma treatment. The drug candidate is a combination treatment that pairs Advair's main ingredient fluticasone with another compound, vilanterol. Advair, which generated about $8.4 billion in 2010 sales, is GSK's top-selling product.

GSK entered a strategic alliance with San Francisco, California-based Theravance in 2004 that gave GSK exclusive access to the biopharmaceutical company's drug discovery programs prior to Sept. 1, 2007. The alliance includes Theravance's drug program for COPD. Under the agreement, GSK is responsible for funding all development, manufacturing, and commercialization of the compounds.

The Motley Fool owns shares of GlaxoSmithKline. Motley Fool newsletter services have recommended buying shares of GlaxoSmithKline. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Read/Post Comments (0) | Recommend This Article (0)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

Compare Brokers

Fool Disclosure

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 1502898, ~/Articles/ArticleHandler.aspx, 10/26/2016 1:15:06 PM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Today's Market

updated Moments ago Sponsored by:
DOW 18,217.76 48.49 0.27%
S&P 500 2,142.74 -0.42 -0.02%
NASD 5,265.99 -17.41 -0.33%

Create My Watchlist

Go to My Watchlist

You don't seem to be following any stocks yet!

Better investing starts with a watchlist. Now you can create a personalized watchlist and get immediate access to the personalized information you need to make successful investing decisions.

Data delayed up to 5 minutes

Related Tickers

10/26/2016 12:59 PM
GSK $40.37 Up +0.05 +0.11%
GlaxoSmithKline CAPS Rating: ***
THRX.DL $0.00 Down +0.00 +0.00%
Theravance CAPS Rating: **